Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976817 | 0.93 | GSK3B (0.53) | MAPK1GSK3BHDAC6MAP2K4HDAC1 | |
| SCHEMBL19976858 | 0.91 | MAPK1 (0.46) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL19976741 | 0.91 | MAPK1 (0.44) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL19976763 | 0.89 | GSK3B (0.52) | MAPK1GSK3BHDAC6MAP2K4HDAC1 | |
| SCHEMBL19976764 | 0.89 | GSK3B (0.48) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL16752836 | 0.86 | HDAC6 (0.45) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL16752833 | 0.86 | HDAC6 (0.45) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL16769264 | 0.86 | HDAC6 (0.45) | MAPK1GSK3BHDAC6MAP2K4CYP1A2 | |
| SCHEMBL19976731 | 0.82 | MAPK1 (0.42) | MAPK1GSK3BHDAC6CYP1A2 | |
| SCHEMBL19976812 | 0.81 | GSK3B (0.51) | MAPK1GSK3BHDAC6MAP2K4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |